Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Prostaglandins Other Lipid Mediat. 2019 Jul 2;144:106353. doi: 10.1016/j.prostaglandins.2019.106353

Figure 5. EP3 antagonist does not affect body composition.

Figure 5.

20 week old CB6F1 mice were administered DG-041 or vehicle by subcutaneous injection twice daily for one week. A. Administration of vehicle with or without DG-041 decreased body mass in mice fed HFD or VHFD (P < 0.01) but not in mice fed control diet (P > 0.99). DG-041 had a minimal effect on body weight as compared to vehicle in any dietary treatment group. B. Body composition of fat mass was assessed by pulsed NMR. DG-041 and vehicle treatment each decreased fat mass in mice fed HFD (P < 0.01) but not control diet (P > 0.99). In mice fed a VHFD, DG-041 decreased fat mass (P = 0.0149) but vehicle had no significant effect (P = 0.2472). DG-041 had a minimal effect on fat mass as compared to vehicle in any dietary treatment group. C. Body composition of lean mass was assessed by pulsed NMR. Lean mass was not significantly affected by DG-041 or vehicle (P > 0.99 for all, except VHFD + vehicle P = 0.0568). DG-041 had a minimal effect on lean mass as compared to vehicle in any dietary treatment group. For all figures N = 4 control + vehicle, 3 control + DG-041, 4 HFD + vehicle, 4 HFD + DG-041, 4 VHFD + vehicle, 5 VHFD + DG-041. Values are expressed as mean ± SEM.